Coats Adapts HeiQ Viroblock for New Product Range
U.K.-based Coats, a leading industrial thread company, is partnering with HeiQ to incorporate HeiQ Viroblock technology into its engineered yarns. The agreement also gives Coats exclusive global access to the technology for use in sewing threads.
The Coats Innovation Hub – America, located in North Carolina, is adapting HeiQ Viroblock technology to create a new range of threads and engineered yarns suitable for application across a wide range of end-use products.
In regard to this development, HeiQ CEO Carlo Centonze, stated, “This technology can be applied to any fabric to add an antiviral efficacy to them. Now with Coats threads and yarns, it is even possible for every stitch holding the fabric together to deliver the same effect, leaving no chance for harmful microorganisms.”
HeiQ Viroblock has been proven effective in laboratory testing against SARS-CoV-2, the virus from the coronavirus family that causes COVID-19. It has been shown to be 99.99 percent effective in 30 minutes in tests conducted with the Peter Doherty Institute for Infection and Immunity in Melbourne, Australia.
“The combination of HeiQ Viroblock technology with our specialist expertise in threads and yarns creates a unique and powerful textile solution for the challenges we see today,” said Ronan Cox, president, performance materials, Coats. “The innovation infrastructure we have built at Coats continues to deliver exciting industry changing concepts that have real large-scale commercial potential.”
Non-toxic and hypoallergenic, HeiQ Viroblock merges microsilver technology to attract virus particles that then combine with vesicle technology to break down the viral membrane within seconds. The microsilver technology uses recycled silver to enhance its sustainable offering, while the vesicle technology is bio-based.